PRESENT POSITION AND ADDRESS >

Prashanth Sunkureddi, M.D., P.A.
Clear Lake Rheumatology
2060 Space Park Dr.
Suite 208
Nassau Bay, Texas 77058
Ph: (281) 957-9127
Fax: (281) 957-9157

Accurate Clinical Research, Inc.
Medical Director and Investigator
Jan. 01, 2009 – Present
2060 Space Park Drive, Suite 212
Nassau Bay, TX 77058
2060 Space Park Drive, Suite 208
Nassau Bay, TX 77058

Clinical Assistant Professor of Medicine
Division of Rheumatology
The University of Texas Medical Branch
301 University Blvd-Route 1165
Galveston, Texas 77555-0759

CERTIFICATION

ECFMG Certification: May 2001

BOARD CERTIFICATION >

Board Certified in Rheumatology, November 2006
Board Certified in Internal Medicine, August 2004

EDUCATION >

COMMUNITY SERVICE | MEMBERSHIPS

Sponsor for Arthritis Foundation (Texas Chapter) :

• Art for Arthritis Bay Area Houston 2007
• Bay Area Houston Arthritis Walk 2008
• Clear Lake Arthritis Walk 2009 - Honoree
• Bay Area Houston Arthritis Walk 2010

Member :

• India Association of Southeast Texas

LECTURES | TALKS | PRESENTATIONS

• “My Achy, Breaky Bones” Christus St. John Hospital, Live Well Conference, May 2011
• Speaker’s Bureau: Pfizer, Novartis, Bristol Myers Squibb, Genzyme Biosurgery, UCB, Cypress Bioscience, Victory Pharma
• “Understanding Osteoporosis”, Freeman Library, Houston, Texas, May 2011
• “Rheumatoid Arthritis”, Public Education Event, August 2010, 2009; Hobby Marriott Hotel, Houston, Texas
• “Rheumatoid Arthritis”, YMCA, Houston, Texas. March 2010
• “Lupus”, Health Occupations Students of America Club, Clear Springs High School, League City, Texas. Jan 2010
• “Rheumatoid Arthritis”, Public Education Event, November, 2009; Hobby Marriott Hotel, Houston, Texas
• “Understanding Arthritis”, November 2009, Freeman Library, Houston, Texas
• “Immunopathogenesis and Immunotherapies of Rheumatic Disease”, Division of Allergy and Immunology Grand Rounds, UTMB, Galveston, Texas 2009
• Speaker: Arthritis Foundation Community Education Forums, Christus St. John Stroke Support Group
• Panelist, “Let’s Talk RA”, Community Arthritis Education Forum, April, 2008. Houston, Texas
• “Joint Hypermobility Syndrome”, Ehlers-Danlos National Foundation, Annual Meeting, Houston, Texas. July 2007
• “Current Concepts in Rheumatoid Arthritis” CME presentation, Christus St. John Hospital, Nassau Bay, Texas; December 2006
• “Understanding Rheumatoid Arthritis”, UTMB Senior Citizen Outreach Program, La Marque, Texas, May 2006
• Faculty Lecturer, “Pediatric Rheumatology Board Review for Pediatricians”, The Osler Institute, Terre Haute, Indiana
• Faculty Lecturer, Fellowship Lecture Series, Division of Rheumatology, The University of Texas Medical Branch, Galveston, Texas
• Host and Speaker, Clear Lake Rheumatology Grand Rounds, Nassau Bay, Texas

TEACHING | ADMINISTRATIVE

• Board of Directors, The Arthritis Foundation, South Texas Chapter. April 2010-present
• Board of Directors, Houston Metropolitan Health Network, 2009-Present
• Committee Member, Capstone Project for Mark Jacques, MD MPH candidate at UTMB; “Gout: An Aeromedical Clinical Practice Guideline”, 2008
• Facilitator: Musculoskeletal Exam Workshop for 2nd year Medical Students at UTMB, 2005 & 2006
• Attending Faculty, Friday AM clinic, UTMB, Galveston, Texas; Supervise fellows, residents and medical students
• Moderator, Rheumatology Journal Club, Rheumatology Fellowship Program, UTMB-Galveston, Texas
• Internal Medicine Board Review-Rheumatology, Internal Medicine Residency Program,
  UTMB
• Preceptor for Community rotations for UTMB students, Residents and Fellows
• CME Committee, Christus St. John Hospital, Nassau Bay, Texas

CLINICAL TRIALS >>

• Principal Investigator, “A Randomized, Double-Blind, Active-Controlled Study of Canakinumab (ACZ885) Pre-Filled Syringes or Reconstituted Lyophilizate Versus Triamcinolone Acetonide for Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients.” – Ongoing
• Principal Investigator, “A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE).” – Ongoing
• Principal Investigator, “A Phase 4, Multicenter, Randomized, 52-Week Study to Evaluate the Routine Assessment of Patient Index Data (Rapid3) Compared to the Clinical Disease Activity Index (CDAI) to Prospectively Predict Treatment Success at 52 Weeks Based on a Treatment Decision at Week 12 in Subjects with Moderate to Severe Rheumatoid Arthritis Receiving Certolizumab Pegol (CZP)” – Ongoing
• Principal Investigator, “A randomized, double-blind, parallel-group study of safety and the effect on clinical outcome of tocilizumab SC versus placebo SC in combination with traditional disease modifying anti-rheumatic drugs (DMARDs) in patients with moderate to severe active rheumatoid arthritis” – Ongoing
• Principal Investigator, “A Phase 2 Multi-Center, Open-Label, Follow-Up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis who Completed Study RA0056” – Ongoing
• Principal Investigator, “A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LY2127399 in Patients with Moderate to Severe Rheumatoid Arthritis (RA) who had an Inadequate Response to Methotrexate Therapy” – Ongoing
• Principal Investigator, “A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients with Rheumatoid Arthritis (RA) with or without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy” - Ongoing
• Principal Investigator, “A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of LY2127399 in Patients with Rheumatoid Arthritis (RA)” – Ongoing
• Principal Investigator, “A Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study with an Active Comparator to Evaluate the Efficacy and Safety of CDP6038 Administered Subcutaneously for 12 Weeks to Subjects with Active Rheumatoid Arthritis Having Previously Failed TNF–Blocker Therapy” - Ongoing
• Principal Investigator, “A Phase II, Multi-Center, Randomized, Double-Blind, Methotrexate Controlled Study To Assess The Clinical Efficacy, Safety, And Tolerability Of CH-4051 In Patients With Active Rheumatoid Arthritis Who Have Shown An Inadequate Response To Methotrexate Monotherapy”- Ongoing
• Principal Investigator, “A Phase III, Two-Part, Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial to Assess the Relative Efficacy and Tolerability of Two Doses of MK 0663/Etoricoxib in Patients with Rheumatoid Arthritis”- Ongoing
• Principal Investigator, “Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects with Gout and Cardiovascular Comorbidities” – Ongoing
• Principal Investigator, “A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Of The Analgesic Efficacy And Safety Of Subcutaneous Administration Of Tanezumab In Patients With Osteoarthritis Of The Knee”-2010
• Principal Investigator, “A Randomized, Controlled Study Of ACZ885 (Canakinumab) On The Treatment And Prevention Of Gout Flares In Patients With Frequent Flares For Whom Nsaids And/ Or Colchicine Are Contraindicated, Not Tolerated Or Ineffective”-2010
• Principal Investigator, “Application of Methotrexate Optimization in Rheumatoid Arthritis”, 2009
• Sub-Investigator, “A phase IIIb, multicenter study with a 12-week double-blind, placebo-controlled, randomized period followed by an open-label, extension phase to evaluate the safety and efficacy of certolizumab pegol administered to patients with active rheumatoid arthritis. Phillip Waller, MD and Accurate Clinical Research; 2009
• Sub-Investigator, “A phase 4, Multicenter, Open-label, Assessor-blinded, Switch Study of the Efficacy and Safety of Infliximab (REMICADE) in Patients with Active Rheumatoid Arthritis who are responding inadequately to Etanercept (ENBREL) or Adalimumab (HUMIRA), 2009
• Sub-Investigator, “A phase 3, Multicenter, Randomized, Double-Blind, Controlled Study of the long term analgesic efficacy and safety of Tanezumab alone or in combination with NSAIDs versus NSAIDs alone in patients with Osteoarthritis of the knee or hip”, 2009
• Co-Investigator, “A Phase III, Multi-Center, Open Label Study to Evaluate the Efficacy, Tolerability and Safety of Abatacept in Subjects with Active Rheumatoid Arthritis on Background Non-Biologic DMARDs who have an Inadequate Response to Anti-TNF Therapy and have Limited Therapeutic Options” UTMB, July 2005-August 2006

PUBLICATIONS >>

• Sunkureddi,P. Gouty Arthritis: Understanding the Disease State and
  Management Options in Primary Care. Advances in Therapy. September 2011 28(9):748-760.
• Kumar S, Pappalardo E, Gonzales EB, Sunkureddi P, Pierangeli S. Isolated Elevation of IgA Anti-Beta 2Glycoprotein I Antibodies with Manifestations of Antiphospholipid Syndrome (APS): A case series of four patients. Lupus. October 2009 18(11):1011-4.
• Eisenberg M, Sunkureddi P, McNearney T, Gonzalez EB. Unusual occurrence of Renal Cell Carcinoma diagnosed in two young Hispanic patients with diffuse systemic sclerosis. Journal of Clinical Rheumatology. December 2007: 13(6): 363-364.
• Karnath B, Sunkureddi P. Extra-intestinal manifestations of hepatogastrointestinal disease. Hospital Physician. July 2006:42(7);51-56
  Sunkureddi P, Contreras J, Eisenberg M,. Photo Dx: Hand pain and swelling in a 63 year old woman. The Journal of Musculoskeletal Medicine. April 2006:23(4);282-284
• Sunkureddi P, Karnath B, Nguyen-Oghalai T. Clinical signs of Gout. Hospital Physician. January 2006:42(1);39-42,47
• Sunkureddi P, Gonzalez EB, Washington R et al. A 39 year old man with chest pain: Cardiovascular manifestations of systemic lupus erythematosus. Cleveland Clinic Journal of Medicine. November 2005:72(11);1050-56
• Sunkureddi P, Baethge B. Eosinophilic gastroenteritis associated with systemic Lupus erythematosus. The Journal of Clinical Gastroenterology. (Letter to the Editor). Oct 2005; 39(9):838-9
• Sunkureddi P, Baethge B. et al. Eosinophilic enteritis associated with systemic lupus erythematosus. Southern Medical Journal. October 2005;98(10):1049-52
• Sunkureddi P, Kumar S, Baethge B. Photo Dx: Persistent Pain and Swelling after an Insect Bite.The Journal of Musculoskeletal Medicine. August 2005:22(8);417-419
• Sunkureddi P, Nguyen-Oghalai T, Jarvis J, Karnath B. Clinical Signs of Dermatomyositis. Hospital Physician. April 2005:41(3);41-44

ABSTRACTS >>

• P Sunkureddi, A So, T Bardin, R Alten, M Bloch, T Kiechle, G Krammer, A Shpilsky and N Schlesinger. Effect of IL-1[beta] Inhibition with Canakinumab Compared to Triamcinolone Acetonide on Pain Intensity and New Flares in Gouty Arthritis Patients with Chronic Kidney Disease Stage 2-5; Oral Presentation; American Society of Nephrology Annual Scientific Meeting, Philadelphia, PA 2011
• Murthy V, Erkan D, Jajoria P, Willis R, Vega J, Barilaro G, Basra G, Hsu E, Martinez L, Jatwani S, Papalardo E, Gonzalez EB, Sunkureddi P, Pierangeli S. Effects of Fluvastatin on Pro-inflammatory and Pro-thrombotic markers in Anti-Phospholipid Antibody positive patients: Preliminary results from an Open-Label Prospective Pilot Study. Oral Presentation: American College of Rheumatology Annual Scientific Meeting, Chicago, IL 2011
• P. Sunkureddi, T. Bardin, R. Alte3, N. Schlesinger, M. Bloch, T. Kiechle, G. Krammer, A. Shpilsky, A. So. Effect of IL-1&beta inhibition with Canakinumab Compared to Triamcinolone Acetonide on Pain Intensity and New Flares in Gouty Arthritis Patients with Chronic Kidney Disease Stage 2-5. American College of Rheumatology Annual Scientific Meeting, Chicago, IL 2011
• Sunkureddi P, Gendreau, J. Demographic, disease and treatment characteristics of the rheumatoid Arthritis population enrolled in the AMORA Study (Applications for Methotrexate Optimization in Rheumatoid Arthritis) in evaluating the Avise PG test. American College of Rheumatology Annual Scientific Meeting, Atlanta, GA 20105
• Martinez LA, Valenzuela R, Seif AM, Papalardo E, Vilá LM, Najam S, McNearney TA, Gonzalez EB, Sunkureddi P, Binder WL, Reveille JD, Norman G, Shums Z, Alarcon GS and Pierangeli SS. Do Clinically Relevant IgA-Anti-B2glycoprotein I (anti-B2GPI) Antibodies Bind to Domain IV/V of β2GPI: American College of Rheumatology Annual Scientific Meeting, Philadelphia, PA 2009
• Rezazadeh B, McNearney TM, Gonzalez EB, Sunkureddi P. Race/Ethnicity is more strongly associated with anti-ccp antibody titers than smoking in rheumatoid arthritis. American College of Rheumatology Annual Scientific Meeting, San Francisco, CA 2008
• Kumar S, Gonzalez EB, Najam S, Pappalardo E, McNearney T, Sunkureddi P, Pierangeli SS. Isolated Elevation of IgA anti-Beta 2 Glycoprotein I antibodies with manifestations of anti-phospholipid antibody syndrome: A case series of five patients. Presented at the 6th International Congress on Autoimmunity, Porto, Portugal, September 2008
• Gonzalez EB, McNearney TM, Sunkureddi P. Higher anti-ccp antibody titers and test sensitivity observed in non-Caucasians with rheumatoid arthritis. EULAR, Barcelona, June 2007
• Sunkureddi P, McNearney TM, Vasquez VT, Gonzalez, EB. Race/Ethnicity differences in anti-CCP antibody in patients with suspected rheumatoid arthritis. American College of Rheumatology Annual Scientific Meeting, San Diego, CA 2006. Arthritis & Rheumatism 2005;52(12):4095
• Gonzalez EB, McNearney TM, Wollaston DE, Sunkureddi P, Lau DT. Prevalence of Hepatitis C infection in an autoantibody-positive population from a university-based rheumatology clinic. American College of Rheumatology Annual Scientific Meeting, San Diego, CA 2006. Arthritis & Rheumatism 2005;52(9):S96.